ArticleMikrochimica acta2025
Au@PdPt nanoparticles-based colorimetric and photothermal dual-mode lateral flow immunoassay for the sensitive detection of ofloxacin.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ofloxacin (OFL) overuse leads to hazardous residues in food and the environment, necessitating sensitive and accurate detection. Traditional gold nanoparticle (AuNP)-based lateral flow immunoassays (LFIAs) suffer from low sensitivity, compromised accuracy, and reliance on single-mode signals, limiting their reliability. We synthesized Au@PdPt nanoparticles (NPs) via a one-step reduction method, integrating a plasmonic Au core with a Pd-Pt alloy shell to enable dual-mode colorimetric and photothermal detection of OFL with enhanced precision. The NPs exhibited broad-spectrum absorption, high photothermal efficiency, and stability. Based on this material, a dual-mode LFIA was developed for OFL, achieving limits of detection (LOD) of 0.059 ng mL⁻
Indexed as
Identifiers
40660027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.